(1) Whether he has been informed that a regulation backlog of nearly 3 000 medicines, which could take another two years to resolve, is being exacerbated by the Medicines Control Council’s (MCC’s) current practice of duplicating tests already conducted in advanced countries; if not, why not; if so, what are the relevant details; (2) whether his department has considered the need for measures to ensure the MCC can automatically accept medication already subjected to stringent regulatory registration elsewhere; if not, why not; if so, what are the relevant details; (3) whether his department has considered the need for new technologies for on-the-spot detection of fake and substandard regulated products to protect the citizens; if not, why not; if so, what are the relevant details?